Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 1
1984 1
1985 3
1986 2
1987 1
1989 3
1990 3
1991 2
1993 1
1994 3
1996 2
1997 1
1998 2
1999 1
2004 2
2005 2
2006 1
2007 1
2008 1
2009 2
2010 3
2011 2
2012 1
2013 7
2014 4
2015 2
2016 3
2017 4
2018 3
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

59 results
Results by year
Filters applied: . Clear all
Page 1
Endothelin receptor antagonists.
Elliott JD, Ohlstein EH, Peishoff CE, Ellens HM, Lago MA. Elliott JD, et al. Among authors: ellens hm. Pharm Biotechnol. 1998;11:113-29. doi: 10.1007/0-306-47384-4_6. Pharm Biotechnol. 1998. PMID: 9760678 Review. No abstract available.
ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.
Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS, Korzekwa K, Swaan PW, Taub ME, Zhao P, Galetin A; International Transporter Consortium. Zamek-Gliszczynski MJ, et al. Among authors: ellens h. Clin Pharmacol Ther. 2013 Jul;94(1):64-79. doi: 10.1038/clpt.2013.45. Epub 2013 Feb 25. Clin Pharmacol Ther. 2013. PMID: 23588311 Free PMC article. Review.
Mechanistic kinetic modeling generates system-independent P-glycoprotein mediated transport elementary rate constants for inhibition and, in combination with 3D SIM microscopy, elucidates the importance of microvilli morphology on P-glycoprotein mediated efflux activity.
Ellens H, Meng Z, Le Marchand SJ, Bentz J. Ellens H, et al. Expert Opin Drug Metab Toxicol. 2018 Jun;14(6):571-584. doi: 10.1080/17425255.2018.1480720. Epub 2018 Jun 7. Expert Opin Drug Metab Toxicol. 2018. PMID: 29788828 Review.
Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria.
Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, Pak YA, Perloff ES, Reyner E, Balimane P, Brännström M, Chu X, Funk C, Guo A, Hanna I, Herédi-Szabó K, Hillgren K, Li L, Hollnack-Pusch E, Jamei M, Lin X, Mason AK, Neuhoff S, Patel A, Podila L, Plise E, Rajaraman G, Salphati L, Sands E, Taub ME, Taur JS, Weitz D, Wortelboer HM, Xia CQ, Xiao G, Yabut J, Yamagata T, Zhang L, Ellens H. Bentz J, et al. Among authors: ellens h. Drug Metab Dispos. 2013 Jul;41(7):1347-66. doi: 10.1124/dmd.112.050500. Epub 2013 Apr 25. Drug Metab Dispos. 2013. PMID: 23620485 Free PMC article.
Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Lee CA, et al. Among authors: ellens h. Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Drug Metab Dispos. 2015. PMID: 25587128 Review.
59 results